Literature DB >> 21350218

Independent prognostic value of screen detection in invasive breast cancer.

Stella Mook1, Laura J Van 't Veer, Emiel J Rutgers, Peter M Ravdin, Anthonie O van de Velde, Flora E van Leeuwen, Otto Visser, Marjanka K Schmidt.   

Abstract

BACKGROUND: Mammographic screening has led to a proportional shift toward earlier-stage breast cancers at presentation. We assessed whether the method of detection provides prognostic information above and beyond standard prognostic factors and investigated the accuracy of predicted overall and breast cancer-specific survival by the computer tool Adjuvant! among patients with screen-detected, interval, and nonscreening-related carcinomas.
METHODS: We studied 2592 patients with invasive breast cancer who were treated at the Netherlands Cancer Institute from January 1, 1990, through December 31, 2000. Overall and breast cancer-specific survival probabilities among patients with mammographically screen-detected (n = 958), interval (n = 417), and nonscreening-related (n = 1217) breast carcinomas were compared. Analyses were adjusted for clinicopathologic characteristics and adjuvant systemic therapy. Because of gradual implementation of population-based screening in the Netherlands, analyses were stratified a priori according to two periods of diagnosis. All statistical tests were two-sided.
RESULTS: Screen detection was associated with reduced mortality (adjusted hazard ratio for all-cause mortality = 0.74, 95% confidence interval = 0.63 to 0.87, P < .001, and adjusted hazard ratio for breast cancer-specific mortality = 0.62, 95% confidence interval = 0.50 to 0.78, P < .001, respectively) compared with nonscreening-related detection. The absolute adjusted reduction in breast cancer-specific mortality was 7% at 10 years. The prognostic value of the method of detection was independent of the period of diagnosis and was similar across tumor size and lymph node status categories, indicating its prognostic value beyond stage migration. Adjuvant! underestimated breast cancer-specific survival in patients with screen-detected (-3.2%) and interval carcinomas (-5.4%).
CONCLUSIONS: Screen detection was found to be independently associated with better prognosis for overall and breast cancer-specific survival and to provide prognostic information beyond stage migration among patients with invasive breast cancer. We propose that the method of detection should be taken into account when estimating individual prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 21350218     DOI: 10.1093/jnci/djr043

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  39 in total

1.  Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.

Authors:  N Kobayashi; M Hikichi; K Ushimado; A Sugioka; Y Kiriyama; M Kuroda; T Utsumi
Journal:  Clin Transl Oncol       Date:  2017-04-13       Impact factor: 3.405

2.  Radiation risk of breast screening in England with digital mammography.

Authors:  Lucy M Warren; David R Dance; Kenneth C Young
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

3.  Breast cancer screening: evidence of benefit depends on the method used.

Authors:  Philippe Autier; Mathieu Boniol
Journal:  BMC Med       Date:  2012-12-12       Impact factor: 8.775

4.  Bahcesehir long-term population-based screening compared to National Breast Cancer Registry Data: effectiveness of screening in an emerging country.

Authors:  Sibel Ozkan Gurdal; Ayse Nilufer Ozaydın; Erkin Aribal; Beyza Ozcinar; Neslihan Cabioglu; Cennet Sahin; Vahit Ozmen
Journal:  Diagn Interv Radiol       Date:  2021-03       Impact factor: 2.630

5.  Impact of mammography detection on the course of breast cancer in women aged 40-49 years.

Authors:  Judith A Malmgren; Jay Parikh; Mary K Atwood; Henry G Kaplan
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

6.  Quality Indicators for Sentinel Lymph Node Biopsy in Breast Cancer: Applicability and Clinical Relevance in a Non-screened Population.

Authors:  Sanjit Kumar Agrawal; Sachin Suresh Shenoy; Nikhil Nalawade; Soumtira Shankar Datta; Soumendranath Roy; Sanjoy Chatterjee; Indu Arun; Rosina Ahmed
Journal:  Indian J Surg Oncol       Date:  2017-08-21

7.  Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.

Authors:  J M N Lopes Cardozo; M K Schmidt; L J van 't Veer; F Cardoso; C Poncet; E J T Rutgers; C A Drukker
Journal:  Breast Cancer Res Treat       Date:  2021-06-30       Impact factor: 4.872

8.  PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.

Authors:  G C Wishart; C D Bajdik; E Dicks; E Provenzano; M K Schmidt; M Sherman; D C Greenberg; A R Green; K A Gelmon; V-M Kosma; J E Olson; M W Beckmann; R Winqvist; S S Cross; G Severi; D Huntsman; K Pylkäs; I Ellis; T O Nielsen; G Giles; C Blomqvist; P A Fasching; F J Couch; E Rakha; W D Foulkes; F M Blows; L R Bégin; L J van't Veer; M Southey; H Nevanlinna; A Mannermaa; A Cox; M Cheang; L Baglietto; C Caldas; M Garcia-Closas; P D P Pharoah
Journal:  Br J Cancer       Date:  2012-07-31       Impact factor: 7.640

9.  Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study.

Authors:  Marina Pollán; Nieves Ascunce; María Ederra; Alberto Murillo; Nieves Erdozáin; Jose Alés-Martínez; Roberto Pastor-Barriuso
Journal:  Breast Cancer Res       Date:  2013-01-29       Impact factor: 6.466

10.  Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series.

Authors:  Anna Crispo; Maddalena Barba; Giuseppe D'Aiuto; Michelino De Laurentiis; Maria Grimaldi; Massimo Rinaldo; Giuseppina Caolo; Massimiliano D'Aiuto; Immacolata Capasso; Emanuela Esposito; Alfonso Amore; Maurizio Di Bonito; Gerardo Botti; Maurizio Montella
Journal:  BMC Cancer       Date:  2013-01-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.